IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Richard Belanger who wrote (316)	1/27/1997 2:06:00 PM
From: I. Luttichuys	of 1762

Hello Rich, I defer to Brad to answer most of what you are asking, with the exception of a small thought I had on reading your post. If I am not mistaken mouse-derived antibodies have had a rather poor record with respect to the elicitation of an immune response in human subjects. Of course this is not specifically derogatory towards IMGN's technology but, it is something which is "out there". I also do not think there is any question as to who will be to market first. I have a pretty clear understanding of where IDEC is with C2B8 at the moment and am somewhat confident we will see good things sooner rather than later. I would not want to select IMGN as a stock based on any reason which has to do with their NHL therapy for these reasons and others. If I bought IMGN, it would be on the weight of whatever other promising technologies they might have. If I have not already said it, your background in radiation dosimetry makes you a very welcome addition to the thread and I will look forward to any observations you will have for us in this area. Have a good afternoon, BENNETT PS: I also own QCOM and about this I have no complaints :o).

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next